GenScript has opened its plasmid manufacturing plant in Zhenjiang, China, which will provide customers with a one-stop service, says firm. According to GenScript ProBio, its second plasmid facility is the largest one in China with a total floor space of 6,400 square-meter, which will support development of cell and gene therapies and messenger RNA (mRNA) drugs. Additionally, the firm claim the plant establishes its position in the contract development manufacturing organization (CDMO) field – providing more than double plasmid production…

Microbial manufacturing capacity will see steady growth over the next few years as molecular pipelines become more heterogenous, say experts. According to biotechnology group BDO’s Fall 2021 bioTRAK report covering the supply and demand of manufacturing capacity for recombinant biopharmaceuticals, current microbial manufacturing capacity totals more than 500kL. There are over 90 companies actively producing products for the global marketplace from 112 manufacturing plants, Dawn Ecker, managing director, bioTRAK Database Services told us. And “looking forward to 2025, microbial capacity…

BioMagnetic Solutions will build a ferrofluid and monoclonal antibody production facility at Innovation Park in Pennsylvania, US.   Gamma Biosciences acquired cell selection and bioseparation firm BioMagnetic Solutions (BMS) in January. Now BMS will construct a 13,000 square-foot production facility in Innovation Park at Penn State, which is expected to be fully operation in mid-2022. BMS claims the company will continue to focus on developing proprietary nanoscale ferrofluids from clinical to development through to commercial scale and the facility will…

The expansion at its Visp, Switzerland facility will support increased capacity of development services targeting microbial-derived proteins, says Lonza. The expansion will see Swiss contract development manufacturing organization (CDMO) Lonza up its microbial development laboratories at its Visp site by 50% as part of the firm’s focus on increasing its microbial service offerings. The investment, of which financial details have not been disclosed, will include the installation of a pilot suite with a 50 L fermenter and downstream equipment to…

Baxter Biopharma Solutions will invest $100 million to expand its fill-finish capabilities at a plant in Halle/Westfalen, Germany. The German facility is operated by Baxter Biopharma Solutions (BPS), the contract development manufacturing organization (CDMO) arm of Baxter International. The $100 million expansion will add a syringe filling line and additional lyophilized and liquid vial capacity. According to the firm, the addition of an aseptic syringe filling line will enable BPS to meet the increased demand for fill-finish services in Europe…